Acadian Asset Management LLC bought a new stake in Genomic Health, Inc. (NASDAQ:GHDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 23,155 shares of the medical research company’s stock, valued at approximately $753,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tributary Capital Management LLC increased its position in shares of Genomic Health by 11.7% in the second quarter. Tributary Capital Management LLC now owns 329,585 shares of the medical research company’s stock valued at $10,728,000 after buying an additional 34,623 shares during the last quarter. Dubuque Bank & Trust Co. increased its position in shares of Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after buying an additional 379 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Genomic Health by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 294,048 shares of the medical research company’s stock valued at $9,259,000 after buying an additional 81,425 shares during the last quarter. Kimelman & Baird LLC increased its position in shares of Genomic Health by 8.2% in the first quarter. Kimelman & Baird LLC now owns 21,040 shares of the medical research company’s stock valued at $663,000 after buying an additional 1,600 shares during the last quarter. Finally, Credit Suisse AG increased its position in shares of Genomic Health by 7.8% in the first quarter. Credit Suisse AG now owns 62,764 shares of the medical research company’s stock valued at $1,977,000 after buying an additional 4,567 shares during the last quarter. 89.53% of the stock is currently owned by institutional investors and hedge funds.

Genomic Health, Inc. (NASDAQ GHDX) traded up 1.00% on Friday, reaching $30.22. The company’s stock had a trading volume of 79,065 shares. Genomic Health, Inc. has a 12 month low of $25.66 and a 12 month high of $33.97. The firm’s market cap is $1.05 billion. The firm’s 50 day moving average is $32.22 and its 200-day moving average is $31.13.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.02. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The company had revenue of $85.50 million during the quarter, compared to analyst estimates of $86.08 million. During the same quarter in the prior year, the business earned ($0.18) EPS. The business’s quarterly revenue was up 4.3% on a year-over-year basis. On average, equities research analysts anticipate that Genomic Health, Inc. will post $0.01 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/acadian-asset-management-llc-invests-753000-in-genomic-health-inc-nasdaqghdx.html.

Several brokerages have recently commented on GHDX. BidaskClub downgraded Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a report on Thursday, August 3rd. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a report on Monday, June 12th. Finally, Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of Genomic Health in a report on Wednesday, May 3rd. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. Genomic Health presently has a consensus rating of “Hold” and an average price target of $32.43.

In other Genomic Health news, insider Steven Shak sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $29.40, for a total value of $147,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Fred E. Cohen sold 8,250 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $30.68, for a total transaction of $253,110.00. Following the completion of the sale, the director now owns 74,145 shares in the company, valued at approximately $2,274,768.60. The disclosure for this sale can be found here. Insiders sold 75,642 shares of company stock worth $2,342,466 in the last 90 days. Company insiders own 46.20% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.